Long-term complications in Hodgkin’s lymphoma survivors

Saadettin Kilickap1, Ibrahim Barista1, Sukran Ulger2, Ismail Celik1, Ugur Selek3, Ibrahim Gullu1, Ferah Yildiz3, Ayse Kars1, Yavuz Ozisik1, and Gulten Tekuzman1

1Department of Medical Oncology, Hacettepe University Institute of Oncology; 2Radiotherapy Center, Ataturk Chest Diseases and Chest Surgery Training and Research Hospital; 3Department of Radiation Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey

ABSTRACT

Background. Although patients with Hodgkin’s lymphoma (HL) achieve prolonged survival, long-term complications are a major cause of morbidity and mortality among long-term survivors of HL.

Methods. We retrospectively evaluated long-term complications in 336 HL survivors treated between January 1990 and January 2006 at the Department of Medical Oncology of the Hacettepe University Institute of Oncology who were >16 years old at presentation. All patients were regularly followed up every 3 months for the first 2 years after complete response, biannually for 3 years, and annually after 5 years.

Results. Median follow-up was 8.5 years. The mean age (±SD) of the patients at the time of diagnosis was 35.7 ± 13.1 years. The male to female ratio was 61%/39%. During follow-up, 29 second malignancies (8.6%) were diagnosed in 28 patients with HL; 22 were solid tumors and 7 were hematological malignancies. Forty-seven (14.0%) of all patients with HL were found to have thyroid abnormalities. During follow-up, 54 (16.1%) patients developed cardiovascular complications. Overall, 29 (8.6%) patients developed late pulmonary toxicities. The cumulative number of chronic viral infections was 13 (3.9%).

Conclusions. Long-term survivors of HL need to be properly followed up not only for disease control but also for evaluation of possible late morbidities to minimize the consequences.

Key words: Hodgkin’s lymphoma, long-term complication, secondary cancer, thyroid abnormality, cardiovascular event.

Conflict of interest: The authors declare that they have no competing interests. There is no financial disclosure for any of the authors.

Correspondence to: Saadettin Kilickap, MD, Associate Professor, Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye, 06100, Ankara, Turkey. Tel +90-312-3052927; fax +90-312-3052910; email skilickap@yahoo.com

Received November 6, 2011; accepted March 26, 2012.